000			01668na a2200229 4500
003			H12O
005			20210625062806.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91902 _aBautista, José M. _eInstituto de Investigación i+12
245	0	0	_aPharmGKB summary: very important pharmacogene information for G6PD. _h[artículo]
260			_bPharmacogenetics and Genomics, _c2012
300			_a22(3):219-28.
500			_aFormato Vancouver: McDonagh EM, Thorn CF, Bautista JM, Youngster I, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for G6PD. Pharmacogenet Genomics. 2012 Mar;22(3):219-28.
501			_aPMID: 22237549
504			_aContiene 116 referencias
520			_aGlucose-6-phosphate dehydrogenase (G6PD) was one of the first genes found to be associated with variable drug response. It is also very polymorphic, with G6PD deficiency found in more than 300 million people worldwide [1]. Here, we provide an overview of G6PD as a very important pharmacogene, and detail genetic variants and haplotypes associated with drug response (Although most G6PD variants are caused by single nucleotide polymorphisms (SNPs) in the coding region of the G6PD gene at the X chromosome, due to the heterogeneity of alleles causing G6PD deficiency; here, we use the term ‘haplotype’ to define the set of linked SNPs in a G6PD variant that are inherited together and that may or may not produce G6PD deficiency).
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/7/pc7522.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c7522 _d7522